GlassScriptPhysician profile
Marian E Thompson
NPI 1063863470
$1,664.80
in general payments reported to CMS, 2019-2025
24 companies · $94.63 in 2025
The $94.63 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $893 · 2023: $325 · 2024: $57.38 · 2025: $94.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441 · Education: $35.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.04 |
| Education | $35.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $227.99 | 2021-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $216.71 | 2021-2023 | |
| Abbvie INC. | $205.11 | 2021-2025 | |
| Novo Nordisk INC | $181.47 | 2021-2022 | |
| Astellas Pharma US INC | $90.53 | 2022-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $89.63 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $88.22 | 2022-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $78.89 | 2022 | |
| Merck Sharp & Dohme LLC | $54.64 | 2022 | |
| Pfizer INC. | $50.22 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $49.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.01 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $45.12 | 2023-2025 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $42.07 | 2021-2022 | |
| Averitas Pharma INC. | $35.95 | 2023 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.24 | 2022 | |
| Hologic Sales and Service, LLC | $23.38 | 2024 | Aptima |
| Amgen INC. | $18.58 | 2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $17.39 | 2022 | |
| Therapeuticsmd, INC. | $15.93 | 2021 | |
| Amarin Pharma, INC. | $15.34 | 2021 | |
| Exact Sciences Corporation | $14.82 | 2023 | Cologuard Collection Kit |
| Seqirus USA INC | $14.78 | 2021 | |
| Abbott Laboratories | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.